Timing of Radiation Pneumonitis in Patients with Stage 3 Non-Small-Cell Lung Cancer Receiving Consolidation Durvalumab after Chemoradiation

Table 3

Characteristics of patients who had early (≤2 months) vs late (>2 months) radiation pneumonitis and the likelihood of having early RP.

	Early RP (≤2 months post-RT)	Late RP (>2 months post-RT)	OR (95% CI)	value
	10 (32%)	21 (68%)
Age, mean (SD)	64.7 (12.0)	66.7 (10.0)	0.98 (0.91–1.06)	0.6
Sex
Male	4 (24%)	13 (76%)	Reference
Female	6 (43%)	8 (57%)	0.41 (0.09–1.92)	0.3
Mean lung dose, Gy, median (range)	16.69 (11.9–17.44)	16.44 (12.86–18.27)	0.94 (0.58–1.52)	0.8
V5Gy, median (range)	57.93 (52.87–62.80)	58.79 (42.36–64.73)	1.01 (0.85–1.21)	0.9
<60	9 (35%)	17 (65%)	Reference
≥60	1 (20%)	4 (80%)	2.11 (0.20–21.89)	0.5
V20Gy, median (range)	28.875 (17.9–35.52)	29.24 (21.04–33.53)	1.03 (0.85–1.27)	0.7
<30	6 (29%)	15 (71%)	Reference
≥30	4 (40%)	6 (60%)	0.6 (0.12–2.91)	0.5
Stage
3a	7 (44%)	9 (56%)	Reference
3b/c	3 (20%)	12 (80%)	0.32 (0.06–1.60)	0.2
Durvalumab
No	8 (42%)	11 (58%)	Reference
Yes	2 (17%)	10 (83%)	0.28 (0.05–1.62)	0.1
Chemotherapy
No	3 (60%)	2 (40%)	Reference
Yes	7 (27%)	19 (73%)	0.25 (0.03–1.79)	0.1
Radiation dose
60Gy	6 (33%)	12 (67%)	Reference
66Gy	4 (31%)	9 (69%)	0.98 (0.76–1.27)	0.9

CI, confidence interval; OR, odds ratio.